CNTB$2.27
Chart
Performance
Key Stats
AI CNTB Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldConnect Biopharma Holdings (CNTB) presents a mixed investment profile. While its focus on inflammatory diseases and a novel drug candidate (rademikibart) offers thematic appeal, current financial performance and valuation metrics suggest a cautious approach. Technical indicators show a generally bullish trend but with some overbought signals. The company is in a clinical-stage, implying significant future growth potential but also high risk.
Thematic
Connect Biopharma is positioned within the growing biopharmaceutical sector, specifically targeting inflammatory diseases with rademikibart. The increasing prevalence of such conditions and advancements in biologics provide a favorable thematic backdrop. However, the company is still in the clinical stage, meaning its success is tied to regulatory approvals and clinical trial outcomes.
Fundamental
Connect Biopharma currently operates at a loss with no revenue from product sales, common for clinical-stage biotechs. Its financial health is primarily supported by its cash reserves. Key financial metrics highlight its stage of development rather than traditional profitability measures.
Technical
Technical indicators suggest a generally bullish trend for CNTB, with moving averages indicating upward momentum. However, some oscillators point to potential overbought conditions, suggesting that a short-term consolidation or pullback could occur.
| Factor | Score |
|---|---|
| Biopharmaceutical Innovation | 80 |
| Market Trends in Inflammatory Diseases | 75 |
| Clinical Stage Risk | 50 |
| Cash Runway | 65 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 40 |
| Balance Sheet Health | 85 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Momentum | 40 |
| Volume Confirmation | 50 |
| Support & Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Recent Performance
The stock has shown significant positive performance over various short-term periods, with a 1-month return of 138.45% and a 6-month return of 130.46%. Year-to-date performance stands at 87.6%.
Positive Moving Average Signals
Multiple moving averages, including Exponential Moving Average (10), (20), (30), (50), (100), and (200), are all showing 'Buy' signals, indicating an upward trend across different timeframes.
Bearish Points (8)
Consistent Net Losses
The company has reported net losses for all periods presented (2021Q4 to 2024Q4), with a significant net loss of -$15,628,000 in 2024Q4. EPS (TTM) is negative at -0.31.
Limited or Zero Revenue in Past Years
For fiscal years 2021, 2022, and 2023, the reported revenue is zero, with revenue only appearing in 2024 ($26,033,000). This indicates a lack of commercialization or very early-stage operations.
Calendar
September 2025
5
Next Earnings Date
H: $-0.22
A: $-0.22
L: $-0.22
Profile
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Seasonals
Price Target
6.83 USD
The 39 analysts offering 1 year price forecasts for CNTB have a max estimate of 7.50 and a min estimate of 6.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor in horse racing and gaming operations (TwinSpires, casinos).
Weight: 95
Major casino and resort operator with regional properties and sports betting presence.
Weight: 93
Regional casino operator across multiple states, similar market focus.
Weight: 92
Regional casino and racetrack operator with a significant sports betting platform.